Zachary Canonico Portfolio
Invests via DIADEMA PARTNERS LP | Managed by Timothy Bassett, Zachary Canonico
Invests via DIADEMA PARTNERS LP
Managed by Timothy Bassett, Zachary Canonico
Automatically Tracked
Zachary Canonico Profile
Operator-turned-angel investor focused on SaaS, fintech and developer tools with hands-on experience scaling product and go-to-market. Zachary Canonico brings founder and engineering experience to early-stage deal sourcing, active board advising, and seed follow-ons; he evaluates capital-efficient business models, unit economics and customer-led distribution. Prior roles span startup founding, product leadership and angel investments across North America, supporting rounds from pre-seed to Series A. Known for operational diligence, founder mentoring and technical due diligence, he networks with venture funds and accelerators to syndicate deals and co-invest. Typical check sizes and sector bias align with high-growth software and platform plays aiming for rapid revenue expansion.
Operator-turned-angel investor focused on SaaS, fintech and developer tools with hands-on experience scaling product and go-to-market. Zachary Canonico brings founder and engineering experience to early-stage deal sourcing, active board advising, and seed follow-ons; he evaluates capital-efficient business models, unit economics and customer-led distribution. Prior roles span startup founding, product leadership and angel investments across North America, supporting rounds from pre-seed to Series A. Known for operational diligence, founder mentoring and technical due diligence, he networks with venture funds and accelerators to syndicate deals and co-invest. Typical check sizes and sector bias align with high-growth software and platform plays aiming for rapid revenue expansion.
Investment Philosophy & Strategy
Operator-led angel investing with a bias toward capital-efficient SaaS, fintech and developer tools; prioritizes businesses with strong unit economics, product-led customer acquisition and clear paths to recurring revenue. Deploys seed to Series A checks with conviction follow-on reserve, favoring hands-on partnerships where technical and GTM scaling add measurable value. Underwrites opportunities by triangulating engineering rigor, founder velocity and early revenue traction, leaning toward rapid revenue expansion but disciplined on churn and CAC payback. Syndicates with funds and accelerators to diversify risk and accelerate portfolio company market access.
Operator-led angel investing with a bias toward capital-efficient SaaS, fintech and developer tools; prioritizes businesses with strong unit economics, product-led customer acquisition and clear paths to recurring revenue. Deploys seed to Series A checks with conviction follow-on reserve, favoring hands-on partnerships where technical and GTM scaling add measurable value. Underwrites opportunities by triangulating engineering rigor, founder velocity and early revenue traction, leaning toward rapid revenue expansion but disciplined on churn and CAC payback. Syndicates with funds and accelerators to diversify risk and accelerate portfolio company market access.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
15.54%
Gain -3.6%
Monthly
0.83%
Yearly
10.44%
Drawdown
19.17%
$226.48M
Equity
Holdings
$226.48M
Investment
$219.19M
$27.03M
Profit -$9.04M
Realized
$19.74M
Unrealized
$7.29M
Dividends
$803,812.14
Goals
Avg. 0% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-3.6%
Profit
-$9.04M
Win %
46%
This Week
Compared To Last Week
Gain
-3.97%
Profit
-$9.36M
Win %
46%
This Month
Compared to last month
Gain
-5.85%
Profit
-$14.06M
Win %
46%
This Year
Compared to last year
Gain
-28.08%
Profit
-$50.71M
Win %
55%
CUE Cue Biopharma, Inc.
+13.45%
+$14,374.47 
TRVI Trevi Therapeutics Inc.
+3.87%
+$11,914.65 
RARE Ultragenyx Pharmaceutical Inc.
+3.17%
+$27,103.05 
PCVX Vaxcyte, Inc.
+3.15%
+$37,516.24 
VTGN VistaGen Therapeutics Inc.
+3.07%
+$1,866.08 
PGEN Precigen Inc.
+3.03%
+$7,464.56 
VYGR Voyager Therapeutics Inc.
+3%
+$44,482.41 
INO Inovio Pharmaceuticals, Inc.
+2.73%
+$16,879.95 
OCGN Ocugen Inc.
+2.48%
+$6,000 
LRMR Larimar Therapeutics Inc.
+2.45%
+$14,164.15 
KOD Kodiak Sciences Inc.
+2.44%
+$160,158.46 
VKTX Viking Therapeutics Inc.
+2.44%
+$367,626.7 
MNKD MannKind Corporation
+2.33%
+$15,879.92 
MNPR Monopar Therapeutics Inc.
+2.23%
+$2,169.2 
CRVS Corvus Pharmaceuticals Inc.
+2.18%
+$63,650.86 
EPRX Eupraxia Pharmaceuticals Inc.
+2.15%
+$5,200 
RCKT Rocket Pharmaceuticals Inc.
+2.14%
+$1,801.1 
PEPG PepGen Inc.
+2.04%
+$4,527.75 
RVMDW Revolution Medicines, Inc. Warrant
+1.68%
+$8,087.2 
CNTB Connect Biopharma Holdings Ltd.
+1.63%
+$6,943.87 
TLPH Talphera Inc.
+1.57%
+$2,103.81 
SEPN Septarna Inc.
+1.37%
+$99.77 
PHAT Phathom Pharmaceuticals Inc.
+1.35%
+$7,645.53 
UPB Upstream Bio, Inc.
+1.31%
+$1,728.72 
RLMD Relmada Therapeutics Inc.
+1.28%
+$17,071.57 
MGNX Macrogenics Inc.
+1.26%
+$30,060 
NVO Novo Nordisk A/S Sponsored ADR
+1.23%
+$7,871.58 
ZYME Zymeworks Inc.
+1.18%
+$38,375.64 
CAPR Capricor Therapeutics Inc.
+1.15%
+$23,426.63 
BIOA BioAge Labs, Inc.
+1.11%
+$12,000 
COGT Cogent Biosciences, Inc.
+1.07%
+$114,258.46 
PRTC PureTech Health plc - ADR
+0.99%
+$1,347.08 
EQ Equillium, Inc.
+0.89%
+$10,846.1 
GLUE Monte Rosa Therapeutics, Inc.
+0.87%
+$29,781.81 
URGN Urogen Pharma Ltd.
+0.73%
+$5,020 
TARS Tarsus Pharmaceuticals Inc.
+0.73%
+$11,673.9 
PRQR ProQR Therapeutics N.V.
+0.69%
+$1,800.83 
VRTX Vertex Pharmaceuticals Incorporated
+0.64%
+$10,924.8 
XERS Xeris Biopharma Holdings, Inc.
+0.52%
+$4,646.11 
MLYS Mineralys Therapeutics, Inc.
+0.42%
+$2,632.07 
INDV Indivior Pharmaceuticals, Inc.
+0.42%
+$11,505.81 
RCUS Arcus Biosciences Inc.
+0.29%
+$16,669.94 
BMRN Biomarin Pharmaceutical Inc.
+0.09%
+$7,040.88 
CRBP Corbus Pharmaceuticals Holdings, Inc.
+0.06%
+$2,199.78 
ENTA Enanta Pharmaceuticals Inc.
+0.04%
+$350.74 
10806XAJ1
0%
$0 
AYTU
0%
$0 
IMCR Immunocore Holdings plc American Depositary Receipt
0%
$0 
PTHS Pelthos Therapeutics Inc.
0%
$0 
TERN Terns Pharmaceuticals, Inc.
0%
$0 
STTK Shattuck Labs Inc.
-5.17%
-$74,943.05 
INCY Incyte Corporation
-4.78%
-$404,970.51 
TENX Tenax Therapeutics Inc.
-3.09%
-$63,806.99 
SPRB Spruce Biosciences Inc.
-2.7%
-$14,010 
ABBV AbbVie Inc.
-2.11%
-$115,478.4 
ELVN Enliven Therapeutics, Inc.
-2.09%
-$236.43 
ANNX Annexon, Inc.
-1.91%
-$11,962.44 
IVA Inventiva S.A.
-1.82%
-$24,667.93 
FHTX Foghorn Therapeutics Inc.
-1.79%
-$5,995.8 
HRMY Harmony Biosciences Holdings, Inc.
-1.74%
-$55,727.69 
ENTX Entera Bio Ltd.
-1.62%
-$462.87 
CORT Corcept Therapeutics Incorporated
-1.58%
-$13,088 
JNJ Johnson & Johnson
-1.54%
-$200,028.12 
CMPS Compass Pathways plc Depositary Receipt
-1.37%
-$5,261.02 
GHRS GH Research plc
-1.33%
-$7,514.08 
ALKS Alkermes plc
-1.31%
-$29,000 
CLYM Climb Biotherapeutics, Inc.
-1.13%
-$36,853.03 
BCYC Bicycle Therapeutics plc American Depositary Receipt
-1.11%
-$21,439.08 
QURE uniQure N.V.
-0.95%
-$8,146.32 
DNTH Dianthus Therapeutics Inc.
-0.92%
-$7,582 
LPCN Lipocine Inc.
-0.89%
-$1,000 
PASG Passage Bio Inc.
-0.86%
-$976.5 
ABVX Abivax SA ADR
-0.78%
-$57,337.72 
BBIO BridgeBio Pharma, Inc.
-0.75%
-$42,655.5 
JAZZ Jazz Pharmaceuticals plc
-0.58%
-$73,590.72 
LLY Eli Lilly and Company
-0.42%
-$28,920 
EYPT EyePoint Pharmaceuticals Inc.
-0.38%
-$8,927.25 
CELC Celcuity Inc.
-0.37%
-$1,753.62 
MAZE Maze Therapeutics Inc.
-0.36%
-$1,315.5 
RNA Avidity Biosciences Inc.
-0.32%
-$100.23 
UNCY Unicycive Therapeutics Inc.
-0.3%
-$2,291.39 
GPCR Structure Therapeutics Inc.
-0.23%
-$7,223.4 
TGTX TG Therapeutics, Inc.
-0.17%
-$17,588.88 
REPL Replimune Group Inc.
-0.14%
-$1,268.32 
PHVS Pharvaris N.V.
-0.06%
-$571.76 
UTHR United Therapeutics Corporation
-0.02%
-$3,276.36 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 355 | Longs Won 132/355 37% | Profit Factor 1.82 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $644,346.44 |
| Average Win $455,608.07 | Best Trade (Mar 31) $5.29M | Sharpe Ratio -9.59 |
| Average Loss -$148,483.18 | Worst Trade (Dec 31) -$5.64M | Z-Score -2.88 (100%) |
| Commissions $0 | Avg. Trade Length 4m 4w 1d | Expectancy $76,136.67 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% |
| Consecutive Losing Trades | 1,524 | 1,372 | 1,220 | 1,067 | 915 | 762 | 610 | 457 | 305 | 152 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
